Brief: Bellerophon Therapeutics Announces First Patient Treated In Phase 3 Clinical Study Of Inopulse® Inhaled Nitric Oxide Therapy For Covid-19
13/07/2020 13:46
July 13 (Reuters) - Bellerophon Therapeutics Inc BLPH.O :
* BELLEROPHON THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED
IN
PHASE 3 CLINICAL STUDY OF INOPULSE® INHALED NITRIC OXIDE THERAPY
FOR COVID-19
Source text for Eikon: ID:nGNX7kV30W
Further company coverage: BLPH.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen